|1.||George, James N: 48 articles (12/2015 - 01/2002)|
|2.||Fujimura, Yoshihiro: 38 articles (07/2015 - 03/2002)|
|3.||Matsumoto, Masanori: 35 articles (10/2015 - 05/2002)|
|4.||Lämmle, Bernhard: 34 articles (02/2015 - 01/2002)|
|5.||Vesely, Sara K: 30 articles (05/2015 - 01/2003)|
|6.||Kremer Hovinga, Johanna A: 29 articles (02/2015 - 09/2003)|
|7.||Veyradier, Agnès: 26 articles (12/2015 - 05/2002)|
|8.||Terrell, Deirdra R: 24 articles (05/2015 - 01/2003)|
|9.||Tsai, Han-Mou: 23 articles (10/2014 - 01/2002)|
|10.||Coppo, Paul: 19 articles (12/2015 - 05/2002)|
|1.||Thrombotic Thrombocytopenic Purpura
11/09/1991 - "A controlled multicentre trial was conducted in France over a period of five years in 40 patients with thrombotic thrombocytopenic purpura (TTP) to try to determine the best treatment of this disease. "
06/01/2003 - "Thrombotic thrombocytopenic purpura (TTP) is a serious hematologic disorder with a high rate of morbidity and mortality when it fails to go into remission. "
05/01/1990 - "The observation of two clinical cases make possible an evaluation of the potential therapeutic activity of platelet function inhibitors in thrombotic thrombocytopenic purpura (TTP). "
01/01/2006 - "New developments in the understanding of thrombotic thrombocytopenic purpura (TTP) provide opportunities for improved patient care. "
07/01/1993 - "In this study we evaluated the effect of serum collected from seven thrombotic thrombocytopenic purpura (TTP) patients, either in the acute phase of the disease or in clinical remission, on the in vitro growth of bone marrow haematopoietic progenitor cells, obtained from the same TTP patients in clinical remission and from normal donors. "
11/20/2008 - "The presence of KIT exon 11-mutant genotype (n = 283) correlated with improved treatment outcome when compared with KIT exon 9-mutant (n = 32) and wild-type (WT; n = 67) genotypes for objective response (complete response [CR]/partial response [PR], 71.7% v 44.4% [P = .007]; and 44.6% [P = .0002], respectively); time to tumor progression (TTP; median 24.7 months v 16.7 and 12.8 months, respectively); and overall survival (OS; median 60.0 months v 38.4 and 49.0 months, respectively). "
03/01/1993 - "Patients whose malignant neoplasms were in complete or partial remission at the time of development of C-TTP/HUS had a significantly higher estimated 1-year survival rate (74%) as compared with a historic control group of patients receiving other treatments (22%, P = 0.0161). "
01/01/2014 - "Progression-free survival (PFS) and time to progression (TTP) are frequently used to establish the clinical efficacy of anti-cancer drugs. "
11/01/2005 - "The median remission time was 3.5 months and time to tumor progression (TTP) was 4.5 months. "
12/01/2004 - "The time to tumor progression (TTP) was 2 to 18 months (median 5 months), and duration of remission was 4 to 14 months (median 8 months). "
|3.||Breast Neoplasms (Breast Cancer)
04/01/2015 - "Progression-free survival and time-to-progression (PFS/TTP) are used commonly as primary end-points in trials evaluating treatments for metastatic breast cancer (MBC). "
04/01/2012 - "To evaluate the trend in the use of primary endocrine treatment (PET) for elderly patients with operable breast cancer and to study mean time to response (TTR), local control, time to progression (TTP), and overall survival. "
07/22/2010 - "In this study we found that TTP expression was lower in invasive breast cancer cells (MDAMB231) compared with normal breast cell lines MCF12A and MCF-10. "
11/18/2008 - "We assessed the association between OS and time-to-progression (TTP) or progression-free survival (PFS) in metastatic breast cancer (MBC) studies. "
12/08/2015 - "Moreover, reconstitution of c-Jun in TTP-expressing breast tumor cells diminishes Wee1 overexpression and promotes cell proliferation. "
|4.||Colorectal Neoplasms (Colorectal Cancer)
10/10/2007 - "Our aims were to determine the correlations between progression-free survival (PFS), time to progression (TTP), and response rate (RR) with overall survival (OS) in the first-line treatment of metastatic colorectal cancer (MCRC), and to identify a potential surrogate for OS. "
06/01/2003 - "For patients with metastatic colorectal cancer, second-line treatment with FOLFOX4 is superior to treatment with LVFU2 in terms of RR, TTP, and relief of TRS."
09/06/2011 - "Two patients with colorectal cancer achieved partial remission and the time to progression (TTP) was 24 and 16 weeks respectively. "
03/01/2010 - "One patient with colorectal cancer experienced a durable partial remission, with a time to progression (TTP) of >8 months. "
12/01/2010 - "Clinical data (response rate, time to progression (TTP) and overall survival (OS)) of 130 colorectal cancer patients have been retrospectively analyzed. "
|5.||Neoplasm Metastasis (Metastasis)
07/01/2008 - "Multivariate analysis was most notable for a significantly greater OS (HR=0.49, P=0.04) and TTP (HR=0.3, P=0.01) associated with peritoneal metastases. "
03/16/2010 - "For 34 patients with CNS metastases, ORR was 21% (95% CI: 9-39%), with evidence of improvement in neurological symptoms, and median TTP was 22 weeks (95% CI: 15-28). "
05/01/2009 - "First-line treatment and non-visceral metastases were associated with longer TTP. "
06/01/2008 - "The variables that were shown to have independent predictive value for the TTP were: non-visceral metastatic disease, single metastases, hormonal receptor positive N/T ratio<2 and disease-free interval (DFI) > or = 24 months. "
11/01/2003 - "The median TTP (time to progression) for patients with liver metastases alone was also longer compared with the liver plus other sites of metastases group in both trials: 10.2 versus 8.8 months (log rank test, P=0.02) in trial 10923 and 8.3 versus 6.7 months (log rank test, P=0.37) in trial 10961. "
|4.||von Willebrand Factor
|6.||Adrenal Cortex Hormones (Corticosteroids)
|9.||erlotinib (CP 358,774)
|2.||Drug Therapy (Chemotherapy)